Liu Guofang, Guo Wei, Wang Hao, Liu Wendi, Lei Liping, Xie Qiaohua, Li Xiaoyan, Zou Shanshan, Wang Peng, Zhou Huabang, Hu Heping
Department of Hepatobiliary Medicine, Shanghai Eastern Hepatobiliary Surgery Hospital, Shanghai, China.
Department of Military Health Statistics, Naval Medical University, Shanghai, China.
Ann Palliat Med. 2021 Apr;10(4):3673-3683. doi: 10.21037/apm-20-1337. Epub 2021 Feb 23.
The effectiveness of postoperative adjuvant transarterial chemoembolization (TACE) on survival and recurrence in tumor-node-metastasis (TNM) stage I intrahepatic cholangiocarcinoma (ICC) after radical resection remains unclear. This study aimed to compare overall survival (OS) and recurrence-free survival (RFS) in TNM stage I ICC patients with and without postoperative TACE.
A retrospective cohort study was conducted on TNM stage I ICC patients who had undergone R0 resections with curative intent in Shanghai Eastern Hepatobiliary Surgery Hospital from January 2012 to December 2016. A total of 269 patients were divided into two groups: (I) 35 patients who received postoperative TACE and (II) 234 patients no TACE. Staging was performed according to the 8th edition of American Joint Committee on Cancer (AJCC) TNM staging system. The tumor-related RFS and OS were estimated by the Kaplan-Meier method. Cox proportional regression model was employed to evaluate the prognosis between the two groups.
In all patients, the median OS was 66.8 months. After R0 resection, adjuvant TACE could not improve the survival of TNM stage I patients, and the OS of the TACE group was not better than that of the non-TACE group (P=0.7070). In addition, in the TACE group, the recurrence rate of TNM stage I ICC patients was statistically significantly higher than that of the non-TACE group (P=0.0328). Multivariable analysis revealed that adjuvant TACE was an independent predictor of worse RFS (HR: 1.88, 95% CI: 1.21-2.93).
Adjuvant TACE after radical surgery failed to prolong the OS and potentially delay recurrence for patients with TNM Stage I ICC. Adjuvant TACE might not be suitable for patients with TNM Stage I ICC.
术后辅助经动脉化疗栓塞术(TACE)对肿瘤-淋巴结-转移(TNM)I期肝内胆管癌(ICC)根治性切除术后的生存及复发的有效性尚不清楚。本研究旨在比较接受和未接受术后TACE的TNM I期ICC患者的总生存期(OS)和无复发生存期(RFS)。
对2012年1月至2016年12月在上海东方肝胆外科医院接受意向性R0切除的TNM I期ICC患者进行一项回顾性队列研究。共269例患者分为两组:(I)35例接受术后TACE的患者和(II)234例未接受TACE的患者。根据美国癌症联合委员会(AJCC)TNM分期系统第8版进行分期。采用Kaplan-Meier法估计肿瘤相关的RFS和OS。采用Cox比例回归模型评估两组之间的预后。
所有患者的中位OS为66.8个月。R0切除术后,辅助TACE不能改善TNM I期患者的生存,TACE组的OS并不优于非TACE组(P = 0.7070)。此外,在TACE组中,TNM I期ICC患者的复发率在统计学上显著高于非TACE组(P = 0.0328)。多变量分析显示,辅助TACE是RFS较差的独立预测因素(HR:1.88,95%CI:1.21 - 2.93)。
根治性手术后辅助TACE未能延长TNM I期ICC患者的OS,且可能延迟复发。辅助TACE可能不适用于TNM I期ICC患者。